Could Axsome Therapeutics Inc (AXSM) Change Direction After Today’s Significant Increase?

September 17, 2017 - By Michael Collier

The stock of Axsome Therapeutics Inc (NASDAQ:AXSM) is a huge mover today! The stock increased 4.21% or $0.2 on September 15, reaching $4.95. About 104,839 shares traded. Axsome Therapeutics Inc (NASDAQ:AXSM) has declined 59.08% since September 17, 2016 and is downtrending. It has underperformed by 75.78% the S&P500.
The move comes after 5 months positive chart setup for the $116.87 million company. It was reported on Sep, 17 by We have $5.10 PT which if reached, will make NASDAQ:AXSM worth $3.51 million more.

Axsome Therapeutics Inc (NASDAQ:AXSM) Ratings Coverage

Among 3 analysts covering Axsome Therapeutics (NASDAQ:AXSM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Axsome Therapeutics had 3 analyst reports since December 14, 2015 according to SRatingsIntel. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, December 15. Ladenburg Thalmann initiated Axsome Therapeutics Inc (NASDAQ:AXSM) on Monday, December 14 with “Buy” rating. The firm earned “Buy” rating on Monday, October 3 by Brean Capital.

More notable recent Axsome Therapeutics Inc (NASDAQ:AXSM) news were published by: which released: “Axsome Therapeutics Reports Second Quarter 2017 Financial Results” on August 09, 2017, also with their article: “Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimer’s …” published on July 17, 2017, published: “Axsome Therapeutics Appoints John Golubieski as Chief Financial Officer” on July 06, 2017. More interesting news about Axsome Therapeutics Inc (NASDAQ:AXSM) were released by: and their article: “An Analysis Of Axsome Therapeutics’ Upcoming Catalysts” published on May 25, 2017 as well as‘s news article titled: “Axsome Therapeutics Sweetens The Deal For Investors” with publication date: August 29, 2017.

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $116.87 million. The Firm is engaged in developing therapies for the management of central nervous system disorders, including pain. It currently has negative earnings. It operates in the business of developing novel therapies for the management of CNS disorders segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.